
    
      This is a double-blind, randomized, placebo-controlled, parallel-arm study in subjects with
      DLB or PDD who have RBD.

      Subjects who meet the randomization criteria will be randomized 1:1 to receive Nelotanserin
      or placebo for 28 days during the double-blind period.
    
  